Drugs / DF9001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05597839 | Nov 2022 → Aug 2025 | cancer | Dragonfly Therapeutics | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-11-07 | Dragonfly Therapeutics | Results Dragonfly to Present Preclinical Data on Clinical-Stage DF6215, its Engineered IL-2R alpha-active Agonist, and DF9001, its EGFR-targeting TriNKET®, at SITC dragonflytx.com ↗
Data show superior anti-tumor activity via EGFR signal inhibition compared to cetuximab in a xenograft mice model, and that DF9001 induces potent in vivo efficacy via immune effector cells, even in cancer models not dependent on EGFR signaling. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-11-07 | Dragonfly Therapeutics | Dragonfly to Present Preclinical Data on Clinical-Stage DF6215, its Engineered IL-2R alpha-active Agonist, and DF9001, its EGFR-targeting TriNKET®, at SITC dragonflytx.com ↗ |
| 2024-05-21 | Dragonfly Therapeutics | Dragonfly Announces Clinical Collaboration to Evaluate DF9001 in Combination with KEYTRUDA® in Patients with Solid Tumors dragonflytx.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DF9001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05597839 ↗ |